Inactive Instrument

Antares Pharma, Inc.

ATRS

US0366421065

Medical Equipment, Supplies & Distribution

Antares Pharma, Inc. Revises Earnings Guidance for the Full Year of 2020

January 11, 2021 at 01:00 pm

Antares Pharma, Inc. also updated its guidance for full-year 2020 and expects revenue to be in a range of $145 to $150 million from $135 to $155 million.

Latest news about Antares Pharma, Inc.

Antares Pharma, Inc. Announces Management Changes	24/05/22	CI
Antares Pharma, Inc.(NasdaqCM:ATRS) dropped from NASDAQ Composite Index	24/05/22	CI
Antares Pharma, Inc.(NasdaqCM:ATRS) dropped from S&P Pharmaceuticals Select Industry Index	24/05/22	CI
Antares Pharma, Inc.(NasdaqCM:ATRS) dropped from S&P Global BMI Index	24/05/22	CI
Antares Pharma, Inc.(NasdaqCM:ATRS) dropped from S&P TMI Index	24/05/22	CI
Halozyme Therapeutics, Inc. completed the acquisition of Antares Pharma, Inc..	22/05/22	CI
Halozyme Says Antitrust Act Waiting Period Expires for Antares Pharma Acquisition	12/05/22	MT
Antares Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	10/05/22	CI
Halozyme Therapeutics Launches Cash Tender Offer to Acquire Antares Pharma Shares	26/04/22	MT
Ladenburg Thalmann Downgrades Antares Pharma to Neutral From Buy	14/04/22	MT
HC Wainwright Downgrades Antares Pharma to Neutral From Buy; Price Target is $5.60	14/04/22	MT
Piper Sandler Downgrades Antares Pharma to Neutral From Overweight, Adjusts Price Target to $5.60 From $6	14/04/22	MT
Raymond James Downgrades Antares Pharma to Market Perform From Strong Buy	14/04/22	MT
Sector Update: Health Care Stocks Putting Up Modest Gains This Afternoon	13/04/22	MT
Health Care Up Amid Deal Activity -- Health Care Roundup	13/04/22	DJ
Sector Update: Health Care Stocks Edging Higher Wednesday Afternoon	13/04/22	MT
Top Midday Gainers	13/04/22	MT
Truist Securities Downgrades Antares Pharma to Hold From Buy, Adjusts PT to $5.60 From $7.00	13/04/22	MT
Halozyme to Acquire Antares Pharma for $960 Million; Antares Shares Surge	13/04/22	MT
Wall Street Set for Muted Open as Traders Digest BlackRock, JPMorgan Earnings; Producer Prices Rise More Than Expected	13/04/22	MT
Sector Update: Health Care Stocks Lean Lower Premarket Wednesday	13/04/22	MT
Top Premarket Gainers	13/04/22	MT
North American Morning Briefing: Stock Futures Tick Up Ahead of Earnings	13/04/22	DJ
Halozyme Therapeutics, Inc. entered into a definitive agreement to acquire Antares Pharma, Inc. for $970 million.	12/04/22	CI
Lipocine's Partner Company Secures US FDA Approval for Testosterone Replacement Therapy	29/03/22	MT

Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself or with partners, therapeutic products using its drug delivery systems. The Company products include XYOSTED (testosterone enanthate) injection, NOCDURNA (desmopressin acetate), OTREXUP (methotrexate) injection, Epinephrine Injection USP, Sumatriptan Injection USP, Makena Subcutaneous Auto Injector and Teriparatide Injection. Its testosterone enanthate injection product is indicated for testosterone replacement therapy (TRT) in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Its desmopressin acetate is used for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken at least two times per night to urinate.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ABBOTT LABORATORIES	-6.68%	179B
MEDTRONIC PLC	-5.20%	98.84B
BECTON, DICKINSON AND COMPANY	-5.38%	65.34B
HOYA CORPORATION	+15.46%	45.41B
DEXCOM, INC.	-6.47%	44.94B
CENCORA, INC.	+9.74%	43.76B
METTLER-TOLEDO INTERNATIONAL, INC.	+14.01%	29.01B
TERUMO CORPORATION	+19.39%	25.65B
WEST PHARMACEUTICAL SERVICES, INC.	-6.53%	23.32B

Other Medical Equipment, Supplies & Distribution